Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab

摘要

Ccute lymphoblastic leukemia (ALL) is a rare form of leukemia, with an estimated 6,250 new cases diagnosed in the United States in 2015 and approximately 1,450 deaths (American Cancer Society, 2015). With current available induction therapies, complete remission (CR) rates in adults are approximately 75% to 90% (Faded et al., 2010; Bas-san & Hoelzer, 2011). After induction therapy, patients with ALL may then receive intensification, consolidation, and maintenance courses of chemotherapy or allogeneic hemato-poietic stem cell transplant (HSCT).